BIOLOGICAL TESTING FACILITY - CONTRACEPTIVE RESEARCH AND DEVELOPMENT TASK ORDER

在内部人口健康研究司(DIPHR)内，避孕药具 NICHD的开发计划(CDP)支持研究开发可能破坏正常的化合物 排卵、精子产生或精子功能，以发展安全、有效和 男性或女性负担得起的避孕药具。生物检测设施(BTF)是 旨在允许快速评估新的物质成分、药物配方、给药 用于避孕和内分泌活动的系统和设备。北京交流会提供总体项目 管理和能力，以支持临床前活动的所有阶段 开发新的避孕方法：这些方法包括但不限于体外和体外 活体分析、血浆和微粒体稳定性研究、吸收、分布、 代谢、排泄和毒性(ADMET)、药代动力学(PK)和药效学(PD) 简介、动物活动和研究、活性药物成分(原料药)的制造、 流程和产品开发、配方、临床批量生产、临床前支持 导致提交研究新药(IND)申请的研究和相关任务。 BTF配制的化合物正在或将在非人类灵长类动物身上进行测试。NICHD保持着 非人灵长类动物群体，用于评估潜在的避孕药 人体受试者的试验。由BTF配制的化合物，根据以下条件制备 目前的良好生产规范(CGMP)将允许对CDP避孕药进行临床评估 临床试验网络(CCTN)。CCTN的调查人员已经制定了评估药物的方案 被该计划确定为高优先级的候选人。BTF一直在与CORS合作 化学合成设施和CCTN以及CCTN的调查人员 为候选化合物的临床批次开发和测试合适的配方。这个 每种候选药物的下一步临床研究取决于是否及时收到临床批次 开始招聘和注册流程。目前正在进行临床试验的药物 临床配方中的。生物检测机构扮演着一个 在CDP的药物开发任务中发挥关键作用。

Within the Division of Intramural Population Health Research (DIPHR), the Contraceptive Development Program (CDP) at NICHD supports research to develop compounds that can disrupt normal ovulation, sperm production or sperm function for the purpose of developing safe, effective and affordable contraceptives for men or women. The Biological Testing Facility (BTF) is designed to allow rapid evaluation of new compositions-of-matter, drug formulations, delivery systems, and devices for contraceptive and endocrine activity. The BTF provides overall project management and the capabilities to support all phases of preclinical activities pursuant to development of new contraceptive methods: these include, but are not limited to in vitro and in vivo assays, plasma and microsomal stability studies, absorption, distribution, metabolism, excretion and toxicity (ADMET), pharmacokinetic (PK) and pharmacodynamic (PD) profiling, animal activities and studies, manufacture of active pharmaceutical ingredients (APIs), process and product development, formulation, clinical lot production, preclinical enabling studies and associated tasks leading to the filing of investigational new drug (IND) applications. Compounds formulated by the BTF are, or will be, tested in non-human primates. NICHD maintains a colony of non-human primates for the purpose of evaluating potential contraceptive agents prior to trials in human subjects. Compounds formulated by the BTF that are prepared under current Good Manufacturing Practices (cGMP) will allow clinical evaluation in the CDP Contraceptive Clinical Trials Network (CCTN). The CCTN investigators have develop protocols to evaluate the drug candidates identified as high priority by the Program. The BTF has been working with the CORs for the Chemical Synthesis Facility and the CCTN and with the investigators in the CCTN to develop and test the appropriate formulations for clinical batches of the candidate compounds. The next clinical study for each candidate drug is dependent on timely receipt of clinical batches to begin the process of recruitment and enrollment. Drugs that are currently in ongoing clinical of the clinical formulations. The Biological Testing Facility plays a critical role in the drug development mission of the CDP.